Axsome Therapeutics Inc. (AXSM)
Company Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.
It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia.
Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation.
The company was incorporated in 2012 and is based in New York, New York.

Country | United States |
IPO Date | Nov 19, 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 712 |
CEO | Dr. Herriot Tabuteau M.D. |
Contact Details
Address: 22 Cortlandt Street New York City, New York United States | |
Website | https://www.axsome.com |
Stock Details
Ticker Symbol | AXSM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001579428 |
CUSIP Number | 05464T104 |
ISIN Number | US05464T1043 |
Employer ID | 45-4241907 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Herriot Tabuteau M.D. | Founder, Chairman, Chief Executive Officer & President |
Mark L. Jacobson M.A. | Chief Operating Officer |
Ari Maizel | Chief Commercial Officer |
Darren Opland | Director of Corporate Communications |
Hunter Murdock Esq. | General Counsel & Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 29, 2025 | 4 | Filing |
May 28, 2025 | 4 | Filing |
May 27, 2025 | 8-K | Current Report |
May 20, 2025 | 4 | Filing |
May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
May 13, 2025 | 8-K | Current Report |
May 05, 2025 | 10-Q | Quarterly Report |
May 05, 2025 | 8-K | Current Report |
Apr 25, 2025 | ARS | Filing |
Apr 25, 2025 | DEFA14A | Filing |